


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Progress West Healthcare Center</p> <p>2. 2 Progress Point Parkway O'Fallon, MO 63368</p>	<p>In accordance with application dated January 19, 2017.</p> <p>3. License number: 24-32642-01 is renewed in its entirety to read as follows:</p>	<p>4. Expiration Date: July 31, 2027</p> <p>5. Docket No.: 030-37397 Reference No.:</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Prepackaged Kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 300 millicuries total</p> <p>D. 100 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any diagnostic study or therapy procedure permitted by 10 CFR 35.300, limited to the oral administration of sodium iodide I-131.</p> <p>D. For use in in-vitro studies.</p>



CONDITIONS

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

24-32642-01

Docket or Reference Number

030-37397

Amendment No. 6

10. Licensed material may be used or stored only at the licensee's facilities located at 2 Progress Point Parkway, O'Fallon, Missouri, 63368

11. The Radiation Safety Officer (RSO) for this license is Constance Courtois, M.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Constance Courtois, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Lannis Elese Hall-Daniels, M.D.

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Meredith Byers, M.D.

10 CFR 35.100 and 35.200

Michael Penny, M.D.

10 CFR 35.100 and 35.200

Joelle Biernacki, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Heather V. Garrett, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Punita Gupta, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Hui Hau Shu, M.D.

10 CFR 35.100 and 35.200

Martin B. Ast., M.D.

10 CFR 35.100 and 35.200

James Kelly, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Diana L. Westerfield, M.D.

10 CFR 35.100 and 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-32642-01

Docket or Reference Number
030-37397

Amendment No. 6

Authorized User(M.D.,D.O.,etc.)

Robert Stachecki, M.D.

Ajay Chapa, M.D.

Paula M. Leiva, M.D.


Material and Use

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

13. The licensee will develop and will implement and maintain written waste disposal procedures for licensed materials in accordance with 10 CFR 20.1101, that also meets requirements of the applicable sections of 10 CFR Part 20, Subpart K, and 10 CFR 35.92.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-32642-01Docket or Reference Number
030-37397

Amendment No. 6

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated January 19, 2017 (ML17031A422)

B. Letter received July 27, 2017 (ML17208A305)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: July 28, 2017By: 

Cassandra F. Frazier
Region 3